- 243 Downloads
The 5α-reductase inhibitor finasteride blocks the conversion of testosterone to dihydrotestosterone (DHT), the androgen responsible for male pattern hair loss (androgenetic alopecia) in genetically predisposed men.
Results of phase III clinical studies in 1879 men have shown that oral finasteride 1 mg/day promotes hair growth and prevents further hair loss in a significant proportion of men with male pattern hair loss. Evidence suggests that the improvement in hair count reported after 1 year is maintained during 2 years’ treatment. In men with vertex hair loss, global photographs showed improvement in hair growth in 48% of finasteride recipients at 1 year and in 66% at 2 years compared with 7% of placebo recipients at each time point. Furthermore, hair counts in these men showed that 83% of finasteride versus 28% of placebo recipients had no further hair loss compared with baseline after 2 years.
The clinical efficacy of oral finasteride has not yet been compared with that of topical minoxidil, the only other drug used clinically in patients with male pattern hair loss.
Therapeutic dosages of finasteride are generally well tolerated. In phase III studies, 7.7% of patients receiving finasteride 1 mg/day compared with 7.0% of those receiving placebo reported treatment-related adverse events. The overall incidence of sexual function disorders, comprising decreased libido, ejaculation disorder and erectile dysfunction, was significantly greater in finasteride than placebo recipients (3.8 vs 2.1%). All sexual adverse events were reversed on discontinuation of therapy and many resolved in patients who continued therapy. No other drug-related events were reported with an incidence ≥1% in patients receiving finasteride. Most events were of mild to moderate severity. Oral finasteride is contraindicated in pregnant women because of the risk of hypospadias in male fetuses.
Conclusions:Oral finasteride promotes scalp hair growth and prevents further hair loss in a significant proportion of men with male pattern hair loss. With its generally good tolerability profile, finasteride is a new approach to the management of this condition, for which treatment options are few. Its role relative to topical minoxidil has yet to be determined.
Finasteride specifically inhibits the type II 5α-reductase enzyme which converts testosterone to dihydrotestosterone (DHT), the androgen responsible for the development of male pattern hair loss in genetically predisposed men. Oral finasteride 1 mg/day significantly reduced serum DHT levels by a median 68.4% in men with male pattern hair loss treated for 1 year. A corresponding 9.1% (median) increase in testosterone levels from baseline was reported, but these levels remained within the normal physiological range.
Oral finasteride 0.2 to 5 mg/day for 4 to 6 weeks reduced DHT levels by up to 65% in the scalp, the desired site of action of finasteride in men with male pattern hair loss.
Finasteride did not affect serum luteinising hormone or follicle-stimulating hormone responses to gonadotropin-releasing hormone stimulation in healthy volunteers, and therefore does not appear to influence the hypothalamic-pituitary-testicular axis. In addition, the drug did not alter serum prolactin, sex hormone-binding globulin, aldosterone or cortisol levels in healthy volunteers. Slight increases in serum estradiol levels were seen but, like testosterone levels, these remained within the normal physiological range and the ratio of testosterone to estradiol was unaltered.
Finasteride 1 mg/day does not appear to significantly affect ejaculate volume or other measures of testosterone-mediated semen production such as sperm motility, morphology and number. In addition, this dosage of finasteride had no clinically significant effects on prostate volume in healthy men aged ≤41 years, but caused a slight reduction in serum prostate-specific antigen levels. Evidence suggests that finasteride has no adverse effects on lipid or bone metabolism.
Peak plasma concentrations of finasteride (9.2 µg/L) were reached 1 to 2 hours after drug administration in healthy volunteers who received a 1 mg/day dosage of finasteride for 17 days. Modest accumulation of finasteride in plasma was reported with repeated administration, but trough concentrations appeared to reach steady state within 3 days.
The oral bioavailability of finasteride (80%) is not affected by the presence of food.
Finasteride undergoes wide tissue distribution (volume of distribution = 76L), with ≈90% of circulating finasteride being protein bound. The drug has been detected in nanogram quantities in seminal fluid but these low levels have no clinical significance.
After oral administration, finasteride is extensively metabolised in the liver to compounds which are then eliminated in the bile (56.8%) and the urine (39.1%). Virtually no unchanged drug is recovered after an oral dose of finasteride. The mean terminal elimination half-life of finasteride 1 mg/day after repeated administration is 4.8 hours.
The elimination of finasteride is slower in elderly (≥70 years) than in younger (45 to 60 years) volunteers, but no dosage adjustment is warranted in the former age group, nor in patients with renal impairment. Reduced renal excretion of finasteride is compensated for by an increase in faecal elimination. There are currently no data on the pharmacokinetic properties of finasteride in patients with hepatic impairment.
Although finasteride is principally metabolised by cytochrome P450 3A4 enzymes within the liver, no clinically significant interactions have been reported between finasteride and digoxin, propranolol, aminophylline, warfarin, glibenclamide (glyburide) or antipyrine.
Oral finasteride 1 mg/day has shown efficacy in men with male pattern hair loss. The clinical use of this dosage of finasteride has been assessed in 3 phase III studies involving 1879 men with vertex or frontal hair loss who were treated for up to 2 years. Finasteride produced statistically significant increases in scalp hair growth from baseline within several months of starting treatment, a finding documented by hair count, patient self-assessment, investigator assessment and pre- and post-treatment clinical assessment based on standardised photos. Importantly, finasteride prevented the further hair loss seen in placebo recipients. In men with vertex hair loss, the mean improvement in hair count reported after 1 year with finasteride was maintained during a further 12 months’ treatment. Global photographs of the vertex area showed improvement in hair growth in 48% of finasteride recipients at 1 year (versus 7% with placebo) and in 66% at 2 years (versus 7% with placebo). Furthermore, vertex hair counts showed that 83% of finasteride versus 28% of placebo recipients had no further hair loss compared with baseline after 2 years. Hair growth was enhanced in patients who switched from placebo to finasteride after 12 months but declined progressively in those switched from finasteride to placebo.
Available data from 1879 patients with male pattern hair loss who received either finasteride 1 mg/day or placebo for 1 year in phase III studies show that finasteride is generally well tolerated. Overall, 7.7% of finasteride and 7.0% of placebo recipients reported mild to moderate treatment-related adverse events (1.4 and 1.6% withdrew). The only events reported more frequently in finasteride than placebo recipients were sexual disorders (3.8 vs 2.1%; p = 0.041), which comprised decreased libido (1.8 vs 1.3%), ejaculation disorders (1.2 vs 0.7%) and erectile dysfunction (1.3 vs 0.7%). These resolved in many men who reported them but remained on therapy and in all men who discontinued therapy because of these adverse events. No other drug-related events were reported with an incidence ≥1% in finasteride recipients.
The incidence of drug-related laboratory events was similar in finasteride and placebo groups (2.6 vs 2.4%). Finasteride had no significant effects on non-scalp body hair.
Dosage and Administration
Finasteride is indicated for the treatment of men with male pattern hair loss. The recommended dosage of finasteride in male pattern hair loss is 1 mg/day, taken with or without food. Daily treatment for 3 months or more is necessary before results are seen, and continued treatment is essential to sustain benefit. Furthermore, the effects of the drug are reversed within 12 months after treatment cessation.
There are no current data to support the use of finasteride in women with androgenetic alopecia. Moreover, pregnant women should not be directly exposed to finasteride by using or handling crushed tablets because of the risk of hypospadias developing in a male fetus.
KeywordsAdis International Limited Placebo Recipient Finasteride Hair Loss Hair Growth
Unable to display preview. Download preview PDF.
- 5.Chen W, Zouboulis CC, Orfanos CE. The 5α-reductase system and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders. Dermatology 1996; 193: 177–84Google Scholar
- 9.Hoffmann R, Eicheler W, Happle R. Finasteride is the main inhibitor of 5α-reductase activity in dermal papillae of human hair follicles [abstract no. 342]. J Invest Dermatol 1998 Apr; 110(4): 529Google Scholar
- 10.Olsen EA. Androgenetic alopecia. In: Disorders of hair growth: diagnosis and treatment. New York: McGraw-Hill, Inc., 1993: 257–83Google Scholar
- 16.Waldstreicher J, Fiedler V, Hordinsky M, et al. Effects of finasteride on dihydrotestosterone content of scalp skin in men with male pattern baldness [abstract]. J Invest Dermatol 1994 Apr; 102: 615Google Scholar
- 18.Denti L, Pasolini G, Sanfelici L, et al. Androgens and lipid metabolism: effects of an inhibitor of 5alpha-reductase (finasteride) on HDL-cholesterol and Lp(a) [abstract]. 66th Congress of the European Atherosclerosis Society 1996 Jul 13–17: 168Google Scholar
- 23.Merck & Co. Propecia (finasteride) prescribing information. West Point (PA), 1997Google Scholar
- 24.MRL clinical study report, multicenter study: a double-blind, randomized, placebo-controlled multicenter study to evaluate the safety of low-dose finasteride in male volunteers. Merck Research Laboratories 1996 (protocol 094) (Data on file)Google Scholar
- 30.Rhodes L, Harper J, Uno H, et al. The effects of finasteride (Proscar) on hair growth, hair cycle stage, and serum testosterone and dihydrotestosterone in adult male and female stumptail macaques (Macaca arctoides). J Clin Endocrinol Metab 1994 Oct; 79: 991–6Google Scholar
- 31.Lasseter K. An open-label, multiple-dose study to investigate the pharmacokinetics of finasteride 1mg administered orally in healthy adult male subjects. MRL clinical study report; Merck Research Laboratories 1997; protocol 102 (Data on file)Google Scholar
- 32.Ohtawa M, Morikawa H, Shimazaki J. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5α-androst-lene-17β-carboxamide, a new type of specific competitive inhibitor of testosterone 5α-reductase, in volunteers. Eur J Drug Metab Pharmacokinet 1991; 16: 15–21PubMedCrossRefGoogle Scholar
- 34.Winchell GA, Gregoire S, Constanzer ML, et al. Pharmacokinetics and oral bioavailability of the 5α-reductase inhibitor finasteride in man [abstract]. Pharm Res 1990 Sep; 7 Suppl.: S–251Google Scholar
- 35.Propecia (finasteride) original NDA application clinical documentation. Merck Research Laboratories. D: clinical efficacy and safety; volume 1.23. (Data on file)Google Scholar
- 36.Gregoire S, Winchell GA, Constanzer M, et al. Multiple dose pharmacokinetics of finasteride, a 5α-reductase inhibitor in men 45-60 and ≥70 years old [abstract]. Pharm Res 1990 Sep; 7 Suppl.: S–53Google Scholar
- 37.Gregorie S, Winchell G, Constanzer M, et al. The effect of renal function on the disposition of finasteride, a new 5α-reductase inhibitor [abstract]. J Clin Pharmacol 1991 Sep; 31: 859Google Scholar
- 39.MRL clinical study report, multicenter study: a 6-month, double-blind, randomized, placebo-controlled, multicenter study followed by a 6-month, double-blind, randomized study extension to determine the effect of low doses of finasteride on hair loss in male patients with androgenetic alopecia (male pattern baldness). Merck Research Laboratories 1996 (protocols 081-00 and 081-10). (Data on file)Google Scholar
- 40.Barber B, Kaufman KD, Kozloff R, et al. Development and validation of a men’s hair growth questionnaire [abstract]. Drug Info J 1997; 31(4): 1409–10Google Scholar
- 41.MRL clinical study report, multicenter study: a double-blind, randomized, placebo-controlled, multicenter study to determine the effect of finasteride on hair loss in men with androgenetic alopecia (male pattern baldness). Merck Research Laboratories 1996 (protocol 087-03). (Data on file)Google Scholar
- 42.MRL clinical study report, multicenter study: a double-blind, randomized, placebo-controlled, multicenter study to determine the effect of finasteride on hair loss in men with androgenetic alopecia (male pattern baldness). Merck Research Laboratories 1996 (protocol 089-03). (Data on file)Google Scholar
- 43.MRL clinical study report, multicenter study: a double-blind,placebo-controlled multicenter study to determine the effect of finasteride in men with androgenetic alopecia and frontal baldness. Merck Research Laboratories 1996 (protocol 092). (Data on file)Google Scholar
- 44.MRL clinical study report (synopsis), multicenter study: a double-blind, placebo-controlled study to investigate the effects of finasteride on DHT and testosterone in scalp skin and sebum. Merck Research Laboratories 1996 (protocol 065). (Data on file)Google Scholar
- 45.Merck & Co. Inc. Worldwide Product Circular: Propecia (finasteride, MSD). USA, 1997Google Scholar
- 49.Pharmacia & Upjohn. Regaine topical solution. UK Data SheetGoogle Scholar
- 54.Roberts J, Hordinsky M, Olsen E, et al. The effect of finasteride in post-menopausal women with androgenetic alopecia [abstract no. 103]. Hair Workshop. Brussels, May 1998Google Scholar